Dogwood Therapeutics Inc. has not released specific financial results in the provided document. However, a significant update involves a strategic transaction completed in Q4 2024, where Dogwood acquired Pharmagesic Holdings, including its novel pain development candidate, Halneuron®. As part of this transaction, CKLS, a publicly listed company on the Hong Kong exchange, received 211,383 shares of Common Stock and 2,108.3854 shares of Series A Preferred Stock, which is convertible into 10,000 shares of common stock each, pending shareholder approval. Additionally, a $20 million strategic financing loan from an affiliate of CK Life Sciences International was converted into 284.2638 shares of Series A-1 Preferred Stock in Q1 2025. Upon conversion of the Preferred Stock, CKLS and its affiliates will hold approximately 90% of Dogwood's common stock on a fully diluted basis. No specific guidance or outlook for sales, revenue, or profits has been disclosed in the document.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.